PADI2 and cancer: To mention only a few, we have observed different expression of the CTCFL gene—oncogene—which is tested as a target gene in the immunotherapy of cancer [37,38], PADI2—a novel angiogenesis-regulating gene, or USP53—which is a novel molecular biomarker for weight control [39].